Biologics

Spinal implant developer Spine Wave has launched its Tempest Allograft Bone Matrix, according to a July 14 news release.

Orthobiologics company Bioventus said July 16 that it has invested $15 million in CartiHeal and agreed on an option structure to acquire the company pending approval of its Agili-C implant. 

Orthobiologics company Baxter has received FDA clearance July 9 for its Altapore Shape Bioactive Bone Graft for spine surgery, according to Biospace.

Regenerative medicine company Aziyo Biologics on June 29 launched OsteoGro V, a viable cell bone matrix to assist with bone repair.

Orthobiologics company Bioventus on June 25 launched its Signafuse bioactive bone graft in a strip format.

Here are four key developments in spinal biologics in the last month:

Biomaterials startup Spiderwort has closed a $3.4 million seed financing round one year after it secured $500,000 in a friends and family funding round, Betakit reports.

Minimally invasive spine therapy company SpineOvations reported favorable results at the midpoint of its DiscSeal clinical trial.

The European Commission recently approved Zolgensma, Novartis' $2.1 million gene therapy drug for spinal muscular atrophy, for infants and children up to 46 pounds.

Orthobiologics company Cerapedics published data from a clinical trial examining the fusion rate of its i-Factor bone graft in noninstrumented lumbar fusion.